Henry Schein
HSIC
$74.21
+0.97%
Henry Schein Inc is a leading global solutions company for healthcare professionals, operating primarily in the Medical Distribution industry. It provides a comprehensive portfolio of dental and medical equipment, consumable products, and value-added services such as financial services, continuing education, and practice management software to office-based practitioners and alternative care sites. The company is a dominant player in the healthcare distribution space, leveraging its extensive logistics network and deep customer relationships to serve as a critical, one-stop-shop for practitioners. The current investor narrative centers on navigating a post-pandemic normalization in demand for dental and medical supplies, with recent financial results showing modest revenue growth, while the market assesses the company's ability to expand margins and integrate its technology and specialty product segments to drive future profitability.…
HSIC
Henry Schein
$74.21
Investment Opinion: Should I buy HSIC Today?
Rating: Hold. The core thesis is that HSIC is a stable, cash-generative business caught in a valuation trap, with its attractive forward multiple fully dependent on an earnings recovery that faces significant execution risk amid margin pressures and technical weakness.
Supporting Evidence: The forward P/E of 12.56x is compelling if achieved, but the trailing P/E of 23.11x and PEG of 3.22 indicate the stock is not cheap on current results. Revenue growth, while positive at 7.71% YoY in Q4, is modest and may not provide sufficient operating leverage. Profitability is stable but stagnant, with operating margins of 5.41% in the latest quarter. The stock trades at a significant discount to its 52-week high (-17.23%), suggesting much of the negative news may be priced in, but the severe underperformance versus the S&P 500 (-23.84% over 1 year) signals a lack of positive catalysts.
Risks & Conditions: The two biggest risks are 1) failure to achieve the forward EPS of $6.74, leading to multiple expansion instead of contraction, and 2) further deterioration in technicals, breaking below the $61.95 support. This Hold rating would upgrade to a Buy if the stock approaches the $62 support level (offering a greater margin of safety) and shows evidence of margin stabilization in upcoming quarters. It would downgrade to a Sell if quarterly revenue growth decelerates below 5% or operating margins fall below 5%. Relative to its own history and the modest growth profile, the stock appears fairly valued to slightly overvalued on a trailing basis, but potentially undervalued on a forward basis if estimates are met.
Sign up to view all
HSIC 12-Month Price Forecast
HSIC presents a classic 'show me' story. The valuation is bifurcated: expensive on trailing earnings (P/E 23.11x) but cheap on forward estimates (P/E 12.56x). The market is skeptical, as evidenced by the stock's persistent downtrend and underperformance. The investment thesis hinges entirely on the company delivering the anticipated earnings recovery. Given the modest revenue growth and lack of margin expansion catalysts, the base case of range-bound trading is most probable. The stance would upgrade to bullish on confirmation of margin improvement and a sustained technical breakout above $83. It would turn bearish on an earnings miss or a breakdown below the $62 support level.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Henry Schein's 12-month outlook, with a consensus price target around $96.47 and implied upside of +30.0% versus the current price.
Average Target
$96.47
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$59 - $96
Analyst target range
Analyst coverage for Henry Schein is limited, with only 5 analysts providing estimates according to the data, which is relatively low for a company of its size and suggests it may be under-followed by the broader institutional research community. The consensus sentiment, based on the provided institutional ratings, appears mixed but leans slightly positive, with firms like Evercore ISI, Barrington Research, JP Morgan, and Baird rating it Outperform or Overweight, while Morgan Stanley maintains an Underweight and others like Mizuho, UBS, Wells Fargo, and Leerink have Neutral or Market Perform ratings. The average EPS estimate for the forward period is $6.74, with a narrow range from $6.69 to $6.81, indicating high conviction in the earnings forecast. The target price range is not explicitly provided in the data, so implied upside/downside cannot be calculated. The tight range in EPS estimates suggests analysts have a firm handle on near-term profitability, but the divergence in ratings (from Underweight to Outperform) points to differing views on the stock's risk/reward profile and future catalysts. The lack of a broad target price consensus and the limited number of analysts covering the stock can contribute to higher volatility and less efficient price discovery, as the stock may be more driven by company-specific news and sector flows than by a deep bench of analyst research and price targets.
Bulls vs Bears: HSIC Investment Factors
The evidence currently tilts bearish, primarily due to the stock's severe technical deterioration, stagnant margins, and high PEG ratio suggesting limited growth for the price. The bull case rests almost entirely on the anticipated earnings recovery implied by the low forward P/E of 12.56x. The single most important tension in the investment debate is whether the company can deliver on the forward EPS estimate of $6.74 to justify its current price, or if margin pressures and modest revenue growth will lead to earnings disappointment and further multiple compression. The significant gap between trailing and forward multiples creates a binary outcome dependent on execution.
Bullish
- Strong Forward Earnings Expectations: The forward P/E of 12.56x is nearly half the trailing P/E of 23.11x, indicating the market is pricing in a significant earnings recovery. Analyst consensus expects forward EPS of $6.74, representing a substantial increase from the most recent quarterly EPS of $0.86 (annualized run-rate of $3.44). This low forward multiple offers a margin of safety if earnings materialize.
- Solid Free Cash Flow Generation: The company generated $561 million in TTM free cash flow, providing strong internal funding for operations and shareholder returns. This robust cash generation supports the balance sheet, evidenced by a healthy current ratio of 1.38, and mitigates the risk associated with its moderate debt-to-equity ratio of 1.14.
- Respectable Return on Equity: HSIC's ROE of 12.27% indicates efficient use of shareholder capital and is a positive signal of management's ability to generate profits from equity. This level of profitability is sustainable for a low-margin distribution business and supports the valuation.
- Low Valuation on Sales Metrics: The stock trades at a Price-to-Sales ratio of 0.70 and an EV/Sales of 1.01, which are low absolute multiples typical of a distribution business. This suggests the market is not pricing in aggressive growth, potentially limiting downside if revenue growth remains stable.
Bearish
- Severe Technical Downtrend & Underperformance: The stock is down 17.23% from its 52-week high and has significantly underperformed the S&P 500 by -23.84% over the past year. Recent momentum is negative, with a -4.99% return over the past month, signaling persistent selling pressure and a breakdown in price support.
- Compressed & Stagnant Profit Margins: Gross margin of 28.92% and net margin of 2.94% are thin and show limited signs of expansion. Operating margin of 5.41% in Q4 2025 was below the TTM average of 5.75%, indicating potential margin pressure that could hinder earnings growth despite revenue increases.
- High PEG Ratio Suggests Overvaluation: A PEG ratio of 3.22, based on trailing earnings, indicates the stock is expensive relative to its historical growth rate. This suggests the market may already be pricing in future growth, leaving little room for multiple expansion unless growth accelerates meaningfully.
- Limited Analyst Coverage & Sentiment: With only 5 analysts providing estimates, the stock is under-followed, which can lead to higher volatility and less efficient price discovery. The mixed ratings (including an Underweight from Morgan Stanley) reflect uncertainty about near-term catalysts and the investment thesis.
HSIC Technical Analysis
The stock is in a pronounced downtrend over the past year, having declined approximately 17.23% from its 52-week high of $89.29. With a current price of $74.21, it is trading at approximately 83% of its 52-week range, positioned much closer to the 52-week low of $61.95 than the high, suggesting the stock is in a period of significant weakness and may be approaching a potential value zone, albeit with the risk of further decline. The 1-year price change of +4.04% is notably weak compared to the S&P 500's +27.88% gain, resulting in a severe relative strength deficit of -23.84%, indicating severe underperformance against the broader market. Recent momentum has been decisively negative, with the stock down -4.99% over the past month and -6.74% over the past three months. This short-term weakness contrasts with the slightly positive 6-month change of +1.10%, indicating the recent sell-off has accelerated and erased earlier gains, signaling a breakdown in any prior stabilization. The stock's beta of 0.82 confirms it is less volatile than the market, but its persistent underperformance suggests company-specific or sector-specific headwinds are driving the price action. Key technical support is clearly defined at the 52-week low of $61.95, while immediate resistance lies near the recent highs around $83.35 from late February. A sustained break below the $61.95 support would signal a continuation of the bearish trend and potentially open the door to further declines. Conversely, a move above the $80-$83 resistance zone would be necessary to suggest a meaningful reversal is underway. The stock's low beta of 0.82 implies it should exhibit less volatility than the market, yet its recent drawdown of -17.23% shows it has not been immune to significant downward pressure, highlighting a defensive but weak technical posture.
Beta
0.82
0.82x market volatility
Max Drawdown
-17.2%
Largest decline past year
52-Week Range
$62-$89
Price range past year
Annual Return
+4.0%
Cumulative gain past year
| Period | HSIC Return | S&P 500 |
|---|---|---|
| 1m | -5.0% | +4.4% |
| 3m | -6.7% | +9.3% |
| 6m | +1.1% | +10.5% |
| 1y | +4.0% | +28.8% |
| ytd | -3.4% | +9.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HSIC Fundamental Analysis
Henry Schein's revenue growth is positive but modest, with Q4 2025 revenue of $3.437 billion representing a 7.71% year-over-year increase. However, examining the sequential quarterly data reveals a mixed picture: revenue grew from $3.168 billion in Q1 2025 to $3.437 billion in Q4 2025, but the year-over-year growth rate has been inconsistent, with Q4 2025's 7.71% being the highest in the provided data. The Healthcare Distribution segment, at $2.953 billion in the latest period, remains the dominant revenue driver, while the Technology segment contributed $221 million, indicating the company's broader solutions strategy. Profitability is stable but characterized by thin margins. The company reported net income of $101 million for Q4 2025, with a net margin of 2.94%. Gross margin for the quarter was 28.92%, which is consistent with the trailing twelve-month gross margin of 29.14%. Operating margin was 5.41% for the quarter, slightly below the TTM operating margin of 5.75%. The key takeaway is that while the company is consistently profitable, its margins are compressed, typical of a low-margin distribution business, and show limited signs of meaningful expansion in recent quarters. The balance sheet shows moderate leverage with a debt-to-equity ratio of 1.14, indicating more debt than equity, which is a point of consideration for financial risk. The company generates solid cash flow, with TTM free cash flow of $561 million, providing ample internal funding for operations and shareholder returns, as evidenced by consistent stock repurchase activity in the cash flow statements. Return on Equity (ROE) stands at 12.27%, which is respectable, and the current ratio of 1.38 indicates sufficient short-term liquidity to meet obligations.
Quarterly Revenue
$3.4B
2025-12
Revenue YoY Growth
+0.07%
YoY Comparison
Gross Margin
+0.28%
Latest Quarter
Free Cash Flow
$561000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HSIC Overvalued?
Given the company's consistent profitability with positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is 23.11x, while the forward P/E is significantly lower at 12.56x. This substantial gap implies the market expects a meaningful recovery in earnings, with forward estimates ($6.74 EPS) nearly double the most recent quarterly EPS (annualized run-rate based on Q4's $0.86). The forward multiple suggests a more reasonable valuation if those earnings materialize. Compared to sector averages (which are not provided in the data), a direct peer comparison is not possible. However, the stock's Price-to-Sales (P/S) ratio of 0.70 and EV/Sales of 1.01 appear low, which is characteristic of a low-margin distribution business. The PEG ratio of 3.22, based on trailing metrics, suggests the stock is not cheap relative to its historical growth rate, indicating the market is not pricing in high future growth expectations. Historically, the stock's own valuation has compressed. The current trailing P/E of 23.11x is below the higher end of its historical range seen in recent years (e.g., over 130x in late 2023 during an earnings trough, and around 16-19x during stronger periods in 2021-2022). The current multiple sits in the mid-to-upper range of its more normalized post-2023 band, suggesting the market has already priced in the earnings recovery to a degree, leaving limited room for multiple expansion without significant earnings beats.
PE
23.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 15x~136x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: HSIC faces risks from its thin and potentially compressible margins. With a net margin of just 2.94% and gross margin of 28.92%, any increase in input costs, shipping expenses, or competitive pricing pressure could directly erode profitability. The company carries moderate financial leverage with a debt-to-equity ratio of 1.14, though this is partially mitigated by strong TTM free cash flow of $561 million. Revenue concentration in the low-growth, competitive healthcare distribution segment ($2.95B of $3.44B in Q4) creates dependency on a business with limited pricing power.
Market & Competitive Risks: The stock's valuation presents a key risk. While the forward P/E of 12.56x appears reasonable, the trailing P/E of 23.11x and PEG of 3.22 suggest the stock is not cheap if growth disappoints. The healthcare distribution industry is highly competitive, with constant pressure on pricing and service levels from larger peers and direct-to-consumer models. The stock's low beta of 0.82 offers some defensive characteristic but has not prevented a 17.23% drawdown, indicating company-specific headwinds are dominant. Limited analyst coverage (5 firms) exacerbates sentiment risk, as negative news can have an outsized impact.
Worst-Case Scenario: The bear case involves a failure to meet forward EPS expectations of $6.74, coupled with a sector-wide de-rating of distribution stocks. This could trigger a wave of analyst downgrades from the current mixed ratings, leading to multiple compression. If the forward P/E reverted to a more distressed level of, for example, 10x on lower earnings, and the stock breached its key technical support at the 52-week low of $61.95, a realistic downside scenario could see the stock fall to the $55-$60 range. From the current price of $74.21, this represents a potential loss of 19% to 26%.
FAQ
The key risks are, in order of severity: 1) Execution Risk: Failure to achieve the forward EPS of $6.74, which would cause the attractive forward multiple to expand rather than contract. 2) Margin Compression Risk: Thin operating (5.41%) and net (2.94%) margins are vulnerable to cost inflation or competitive pricing, directly impacting earnings. 3) Technical & Sentiment Risk: The stock is in a pronounced downtrend, down 17.23% from its high, and severe underperformance may continue regardless of fundamentals. 4) Financial Risk: Moderate leverage with a debt-to-equity ratio of 1.14, though mitigated by strong free cash flow.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $70 and $80, as it meets modest earnings expectations but lacks catalysts for multiple expansion. The Bull Case (25% probability) projects a range of $85 to $92, requiring successful execution on the $6.74 EPS target and a market re-rating. The Bear Case (15% probability) warns of a decline to $58-$65 if earnings disappoint and the stock breaks key support. The base case is most likely, centered on the company hitting its EPS target but struggling to improve its growth profile or margins significantly.
HSIC's valuation is schizophrenic, appearing both overvalued and undervalued depending on the timeframe. On trailing earnings (P/E 23.11x) and growth (PEG 3.22), it looks expensive. However, on forward earnings (P/E 12.56x) and sales (P/S 0.70), it appears cheap. This discrepancy means the market is pricing in a substantial earnings recovery. Relative to its own history, the trailing multiple is in a normalized range, suggesting the market has priced in the recovery to a degree. The stock is fairly valued to slightly overvalued on current results but could be undervalued if forward estimates are met. The valuation implies the market expects nearly a doubling of annualized earnings.
HSIC is a conditional buy for patient, value-oriented investors. The forward P/E of 12.56x offers value if the company hits its $6.74 EPS target, representing significant earnings growth. However, the stock carries substantial execution risk, as evidenced by thin margins (net margin 2.94%) and severe technical underperformance (-23.84% vs. S&P 500 over one year). It is a good buy for investors who believe in the earnings recovery story and can tolerate near-term volatility, but a poor choice for those seeking growth or momentum. A more attractive entry point may emerge if the stock tests its 52-week low support near $62.
HSIC is more suitable for a long-term (2+ year) investment horizon. As a low-beta (0.82), defensive business, it is not a compelling short-term trading vehicle due to its weak momentum and lack of near-term catalysts. Long-term investors can benefit from the company's stable cash flows and potential valuation normalization if the earnings recovery materializes. The stock does not pay a dividend, so total return is dependent on price appreciation. Given the execution risk and time required for the forward earnings story to play out, a patient, long-term approach is necessary. Short-term traders should look elsewhere due to the stock's weak relative strength and range-bound technicals.